Results 141 to 150 of about 62,685 (235)
Solitary urothelial carcinoma penile metastasis on <sup>18</sup>F-FDG PET/CT. [PDF]
Svasti J +5 more
europepmc +1 more source
Urothelial carcinoma with paraneoplastic leukocytosis [PDF]
C W, Hsu, H Y, Su
openaire +2 more sources
Abstract Background Accurate cytologic classification of thyroid nodules is essential for clinical management, but interobserver variability and indeterminate interpretations remain persistent challenges. The clinical feasibility of AIxTHY, a disease‐specific deep‐learning algorithm integrated into a digital cytology platform, was evaluated for ...
Swati Satturwar +12 more
wiley +1 more source
Utility of GATA3, Uroplakin-II, and p40 Markers in the Diagnosis of Urothelial Carcinoma. [PDF]
Manjari L, M R A, K R R, P O V, H S.
europepmc +1 more source
What Is Your Diagnosis? Fine‐Needle Aspirate From a Lingual Mass in a Cat
Veterinary Clinical Pathology, EarlyView.
Emma Stacey +3 more
wiley +1 more source
ABSTRACT Nephrogenic adenoma (NA) is a benign lesion of the genitourinary tract that may mimic malignancy both clinically and histologically. The fibromyxoid variant (FMNA), characterized by spindled cells in myxoid stroma, presents additional diagnostic challenges due to its rarity and overlapping features with renal cell carcinoma (RCC).
Jodi Gedallovich +4 more
wiley +1 more source
Upper Tract Urothelial Carcinoma: Molecular Pathogenesis and Current Treatment Strategies-A Narrative Review. [PDF]
Zawadzki D +9 more
europepmc +1 more source
ABSTRACT Pelvic lymph node dissection is an essential component of radical cystectomy (RC) for bladder cancer (BC), but the optimal extent of lymphadenectomy remains uncertain. We conducted a systematic review and meta‐analysis to compare oncologic and perioperative outcomes between extended and non‐extended lymphadenectomy during RC for BC.
Maria Fernanda Dias Azevedo +12 more
wiley +1 more source
Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma. [PDF]
Yamashita T +5 more
europepmc +1 more source
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta +2 more
wiley +1 more source

